Roche Holding AG (RHHBF)
Roche Holding AG operates in the Drug Manufacturers - General industry of the Healthcare sector, headquartered in Basel, BS, CH. The stock last traded at $434.75, down 5.08% on the session, giving a market capitalisation of $346.39B. On trailing twelve-month figures it carries a trailing P/E of 23.46, a net margin of 20.3%. Its beta of 0.35 implies it has historically moved less than the broad market.
Founded in 1896 and headquartered in Basel, Switzerland, Roche Holding AG is a global enterprise active in both the pharmaceutical and diagnostics sectors. Its extensive operations cover numerous countries, including Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium, alongside other international markets. The company's pharmaceutical division develops and provides therapies addressing a broad spectrum of medical conditions. These include cancer (oncology), neurological disorders, infectious diseases, immunological conditions, cardiovascular and metabolic issues, ophthalmological ailments, and respiratory illnesses. Furthermore, its product portfolio extends to treatments for anemia, dermatological problems, hemophilia, inflammatory and autoimmune diseases, and conditions related to organ transplantation. Within its diagnostics business, Roche provides a range of in vitro tests designed for identifying various diseases, such as cancer, diabetes, COVID-19, hepatitis, and human papillomavirus, among others. Complementing this, it also furnishes essential diagnostic instruments and chemical reagents. A significant research collaboration is in place with Synlogic, Inc., aimed at discovering a novel synthetic biotic treatment for inflammatory bowel disease (IBD).
Roche Holding AG is most often compared with the following Healthcare names: